nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT00068003,Cell Harvest and Preparation for Surgery Branch Treatment Protocols,,Enrolling by invitation,Observational,Melanoma; Gastrointestinal Cancer; Metastatic Cancer; Breast Cancer; Non-Small Cell Lung Cancer,Anti-CD19 CAR PBL,,National Cancer Institute (NCI),,7000,2003-09-08,,United States,No,https://clinicaltrials.gov/study/NCT00068003
NCT00900419,Biomarkers and Dysplastic Respiratory Epithelium,,Recruiting,Observational,Esophageal Cancer; Head and Neck Cancer; Lung Cancer; Precancerous Condition,immunohistochemistry staining method; laboratory biomarker analysis; sputum cytology; biopsy,,"University of Colorado, Denver",National Cancer Institute (NCI),700,2001-05-03,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT00900419
NCT02178163,A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.,Not Applicable,Recruiting,Interventional,Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer,cytology specimen collection procedure; laboratory biomarker analysis,,Barbara Ann Karmanos Cancer Institute,National Cancer Institute (NCI),1020,2014-08-01,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT02178163
NCT02596490,Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners,Not Applicable,Recruiting,Interventional,Lung Cancer,Questionnaires; Meditation and Discussion Sessions; Cancer-Related Discussion Program,,M.D. Anderson Cancer Center,"National Cancer Institute (NCI); American Cancer Society, Inc.",300,2016-04-06,2026-12-01,United States,No,https://clinicaltrials.gov/study/NCT02596490
NCT03476681,Phase 1/2 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors,Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer,NEO-201 in combination with pembrolizumab,,"Precision Biologics, Inc",,121,2019-01-18,2029-01-15,United States,No,https://clinicaltrials.gov/study/NCT03476681
NCT03586453,A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Osimertinib,,Dana-Farber Cancer Institute,AstraZeneca,30,2018-08-13,2027-03-01,United States,No,https://clinicaltrials.gov/study/NCT03586453
NCT03740256,A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Phase 1,Recruiting,Interventional,Bladder Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Salivary Gland; Lung Cancer; Breast Cancer; Gastric Cancer; Esophageal Cancer; Colorectal Cancer; Pancreatic Adenocarcinoma; Solid Tumor,CAdVEC,,Baylor College of Medicine,The Methodist Hospital Research Institute,45,2020-12-14,2038-12-30,United States,No,https://clinicaltrials.gov/study/NCT03740256
NCT03774758,Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening,,Recruiting,Observational,Nodule Solitary Pulmonary; Non-small Cell Lung Cancer,Guardant Health ct-DNA LUNAR assay,,"University of California, San Francisco","Northern California Institute of Research and Education; Guardant Health, Inc.",590,2017-12-17,2025-12-31,United States,No,https://clinicaltrials.gov/study/NCT03774758
NCT03948100,"Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers",Not Applicable,Recruiting,Interventional,Esophageal Carcinoma; Lung Non-Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage IA1 Lung Cancer AJCC v8; Stage IA2 Lung Cancer AJCC v8; Stage IA3 Lung Cancer AJCC v8; Stage IB Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage IIA Lung Cancer AJCC v8; Stage IIB Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Educational Intervention; Quality-of-Life Assessment; Questionnaire Administration; Yoga,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),400,2018-12-20,2027-04-30,United States,No,https://clinicaltrials.gov/study/NCT03948100
NCT03987555,Pilot Feasibility Study of Paclitaxel Therapeutic Drug Monitoring in Cancer Patients,,Recruiting,Observational,"Solid Tumor, Adult; Metastatic Nonsmall Cell Lung Cancer; Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Cervical Carcinoma; Metastatic Ovarian Carcinoma; Malignant Uterine Neoplasm; Vulvar Cancer; Invasive Breast Cancer; Metastatic Breast Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Recurrent Breast Carcinoma; Recurrent Cervical Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Vulvar Carcinoma; Stage IV Cervical Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Vulvar Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVA Cervical Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVA Ovarian Cancer AJCC v8; Stage IVA Vulvar Cancer AJCC v8; Stage IVB Cervical Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Stage IVB Ovarian Cancer AJCC v8; Stage IVB Vulvar Cancer AJCC v8; Vulva Squamous Cell Carcinoma",Blood draws; QLQ-CIPN20 Survey; PR-CTCAE Survey,,Wake Forest University Health Sciences,National Cancer Institute (NCI),20,2019-11-11,2026-07-05,United States,No,https://clinicaltrials.gov/study/NCT03987555
NCT04093167,"A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Pembrolizumab,,Canadian Cancer Trials Group,"Cancer Research Institute, New York City; Personal Genome Diagnostics; Mark Foundation for Cancer Research",230,2020-05-26,2027-07-30,Canada; United States,No,https://clinicaltrials.gov/study/NCT04093167
NCT04119024,Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors,Phase 1,Recruiting,Interventional,Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IV Cutaneous Melanoma AJCC v8; Recurrent Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Uveal Melanoma; Acral Melanoma; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Adrenocortical Carcinoma; Pancreatic Neuroendocrine Tumor; Thyroid Cancer; Breast Cancer; Lung Adenocarcinoma; Head and Neck Squamous Cell Carcinoma,Biopsy; Biospecimen Collection; Computed Tomography; Cyclophosphamide; Fludarabine Phosphate; Fludeoxyglucose F-18; IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells; Magnetic Resonance Imaging; Positron Emission Tomography,,Anusha Kalbasi,Parker Institute for Cancer Immunotherapy; Melanoma Research Alliance; California Institute for Regenerative Medicine (CIRM); City of Hope National Medical Center; Jonsson Comprehensive Cancer Center,18,2025-10-07,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04119024
NCT04130516,"A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",Phase 1/Phase 2,Recruiting,Interventional,"Solid Tumor, Adult","LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER; Pembrolizumab - anti-PD-1 antibody",,"Linnaeus Therapeutics, Inc.",Merck Sharp & Dohme LLC,200,2019-10-21,2027-12-15,United States,No,https://clinicaltrials.gov/study/NCT04130516
NCT04165798,"KEYMAKER-U01 Master Study: A Phase 1/2, Umbrella Study With Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants With Non-small Cell Lung Cancer (NSCLC)",,Recruiting,Observational,"Carcinoma, Non-Small-Cell Lung",Tumor Imaging; Tumor Tissue Collection; Blood Sample Collection,,Merck Sharp & Dohme LLC,Daiichi Sankyo,1065,2019-12-19,2032-02-13,Hungary; Israel; Italy; Poland; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04165798
NCT04253964,Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy,Phase 2,Recruiting,Interventional,Nonsmall Cell Lung Cancer; Performance Status,"Pembrolizumab; Carboplatin; Paclitaxel; Nab paclitaxel; Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13); QLQ-C30 Global Health/Quality of Life Questionnaire; COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes; Pemetrexed",,Wake Forest University Health Sciences,National Cancer Institute (NCI),80,2020-07-01,2026-03-05,United States,No,https://clinicaltrials.gov/study/NCT04253964
NCT04300556,"A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,Farletuzumab ecteribulin; Prednisone; Prednisolone; Dexamethasone; Lenvatinib,,Eisai Inc.,,182,2020-08-06,2030-08-08,France; Japan; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04300556
NCT04317534,A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153,Phase 2,Recruiting,Interventional,"NSCLC, Stage I",Pembrolizumab,,"Greg Durm, MD",Merck Sharp & Dohme LLC,244,2020-05-05,2029-04-01,United States,No,https://clinicaltrials.gov/study/NCT04317534
NCT04429542,"First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Head and Neck Squamous Cell Carcinoma; Squamous Cell Carcinoma of Anal Canal; Colorectal Cancer; Squamous Cell Carcinoma of the Lung; EGFR Amplification; Epithelial Ovarian Cancer; Pancreas Cancer; Cutaneous Squamous Cell Carcinoma; Head and Neck Neoplasms; Carcinoma, Squamous Cell; Squamous Cell Carcinoma of Head and Neck",BCA101; Pembrolizumab,,Bicara Therapeutics,Merck Sharp & Dohme LLC,292,2020-06-01,2027-06-01,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT04429542
NCT04486833,"A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung",quaratusugene ozeplasmid; osimertinib; Platinum-Based Chemotherapy,,"Genprex, Inc.",,158,2021-09-03,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT04486833
NCT04499053,A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small Cell Lung",Durvalumab; Tremelimumab,,Georgetown University,AstraZeneca,18,2020-12-09,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT04499053
NCT04585477,Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E),Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage I; Non-small Cell Lung Cancer Stage II; Non-small Cell Lung Cancer Stage III,AVENIO ctDNA Surveillance Kit; Durvalumab; Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy,,Stanford University,AstraZeneca,80,2021-04-08,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT04585477
NCT04762199,"A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8,Flt3/MerTK Inhibitor MRX-2843; Osimertinib,,Emory University,National Cancer Institute (NCI),69,2021-02-24,2026-12-27,United States,No,https://clinicaltrials.gov/study/NCT04762199
NCT04777994,A Phase 1 Study With ABBV-CLS-484 Alone and in Combination in Subjects With Locally Advanced or Metastatic Tumors,Phase 1,Recruiting,Interventional,Advanced Solid Tumor Cancer,ABBV-CLS-484; Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI); Programmed Cell Death-1 (PD-1) Inhibitor,,Calico Life Sciences LLC,,248,2021-03-09,2026-10-05,France; Israel; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04777994
NCT04868877,"Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer Metastatic; Gastric Cancer; Esophageal Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Colorectal Cancer,MCLA-129; Osimertinib; Chemotherapy,,Merus N.V.,,576,2021-04-28,2027-03-05,Belgium; France; Germany; Italy; Netherlands; Singapore; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT04868877
NCT04892953,Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE),Phase 2,Recruiting,Interventional,Stage III Lung Cancer AJCC v8; Stage III Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Cancer AJCC v8; Stage IIIA Lung Non-Small Cell Cancer AJCC v7; Stage IIIB Lung Cancer AJCC v8; Stage IIIB Lung Non-Small Cell Cancer AJCC v7; Stage IIIC Lung Cancer AJCC v8,Carboplatin; Durvalumab; Gemcitabine; Local Consolidation Therapy; Nab-paclitaxel; Paclitaxel; Pemetrexed; Quality-of-Life Assessment; Questionnaire Administration,,M.D. Anderson Cancer Center,,51,2021-07-07,2026-09-30,United States,No,https://clinicaltrials.gov/study/NCT04892953
NCT04991025,Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers,Phase 2,Recruiting,Interventional,Lung Cancer; Lung Cancer Stage II; Lung Cancer Stage III,Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Certolizumab; Nivolumab,,Memorial Sloan Kettering Cancer Center,,60,2022-10-19,2026-10-05,United States,No,https://clinicaltrials.gov/study/NCT04991025
NCT05005403,"A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Micro Satellite Stable Colorectal Cancer; Gastric/Esophageal Cancer; High-Grade Serous Ovarian Cancer; Pancreatic Cancer; Triple Negative Breast Cancer,Azirkitug; Budigalimab; Bevacizumab,,AbbVie,,512,2021-11-01,2027-06-05,Israel; Japan; South Korea; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT05005403
NCT05059444,ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation,,Recruiting,Observational,Bladder Carcinoma; Ureter Carcinoma; Renal Pelvis Carcinoma; Non-small Cell Lung Cancer; Invasive Breast Carcinoma; Cutaneous Melanoma; Esophageal Carcinoma; Gastroesophageal Junction Carcinoma; Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Squamous Cell Carcinoma of the Head and Neck; Epithelial Ovarian Carcinoma; Fallopian Tube Carcinoma; Endometrial Carcinoma; Renal Cell Carcinoma; Rectal Adenocarcinoma,Guardant Reveal,,"Guardant Health, Inc.",,2020,2021-09-07,2029-08-05,France; Germany; Italy; Spain; United States,No,https://clinicaltrials.gov/study/NCT05059444
NCT05076760,Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors,Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Cutaneous Squamous Cell Carcinoma; Merkel Cell Carcinoma; Melanoma; Pancreatic Cancer; Triple Negative Breast Cancer; Head and Neck Cancer,MEM-288 Intratumoral Injection; Nivolumab; Docetaxel,,"Memgen, Inc.",H. Lee Moffitt Cancer Center and Research Institute; Duke Cancer Institute,40,2022-04-21,2031-12-05,United States,No,https://clinicaltrials.gov/study/NCT05076760
NCT05094336,"A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced MTAP-null Solid Tumors,AMG 193; Docetaxel; Comparator AMG 193 Test Tablet,,Amgen,,649,2022-02-01,2028-06-01,Australia; Austria; Belgium; Canada; China; France; Germany; Hong Kong; Japan; South Korea; Switzerland; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05094336
NCT05098132,A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects With Front-line Advanced NSCLC and Other Selected Indications,Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Non Small Cell Lung Cancer; Untreated Advanced NSCLC; 1st Line NSCLC,STK-012; pembrolizumab; pemetrexed; carboplatin,,Synthekine,,364,2022-01-25,2029-01-05,United States,No,https://clinicaltrials.gov/study/NCT05098132
NCT05118854,A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation,Phase 2,Recruiting,Interventional,Lung Cancer,AMG 510; Cisplatin; Carboplatin; Pemetrexed,,M.D. Anderson Cancer Center,Amgen,27,2022-03-30,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT05118854
NCT05121051,"Phase II Randomized, Double Blind, Placebo-Controlled Trial of Broccoli Seed and Sprout Extract (BSSE), Avmacol ES, to Evaluate Sustained Detoxification of Tobacco Carcinogens in Heavy Smokers",Phase 2,Recruiting,Interventional,Cigarette Smoking-Related Carcinoma,Biospecimen Collection; Broccoli Sprout/Broccoli Seed Extract Supplement; Placebo Administration; Questionnaire Administration,,National Cancer Institute (NCI),,135,2022-09-21,2027-12-31,United States,No,https://clinicaltrials.gov/study/NCT05121051
NCT05123482,"A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)",Phase 1/Phase 2,Recruiting,Interventional,Breast Cancer; Biliary Tract Carcinoma; Ovarian Cancer; Endometrial Cancer; Squamous Non-Small Cell Lung Cancer,AZD8205; AZD8205 and AZD2936 (Rilvegostomig); AZD8205 and AZD5305 (saruparib); AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig); AZD8205 in combination with AZD9574; AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936),,AstraZeneca,,460,2021-10-18,2027-09-29,Australia; Belgium; Canada; China; Hungary; Italy; Japan; Netherlands; Poland; South Korea; Spain; Taiwan; Thailand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05123482
NCT05168566,"A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)",Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer,Sutetinib Maleate Capsule,,Teligene US,,99,2022-09-01,2026-06-05,China; United States,No,https://clinicaltrials.gov/study/NCT05168566
NCT05261399,"A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",Phase 3,Recruiting,Interventional,Carcinoma; Non-Small-Cell Lung,Savolitinib; Osimertinib; Pemetrexed; Cisplatin; Carboplatin,,AstraZeneca,,324,2022-08-03,2026-12-17,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Netherlands; Philippines; Poland; Russia; Singapore; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT05261399
NCT05267626,"A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma; Non-Small Cell Lung Cancer,AU-007; Aldesleukin; Avelumab; Nivolumab,,"Aulos Bioscience, Inc.",,159,2022-04-04,2026-06-12,Australia; United States,No,https://clinicaltrials.gov/study/NCT05267626
NCT05277051,"A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Neoplasms,Remzistotug; Dostarlimab; Belrestotug; Nelistotug; GSK5764227,,GlaxoSmithKline,,158,2022-03-22,2027-08-31,Australia; Canada; China; France; Japan; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05277051
NCT05332925,Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN),,Recruiting,Observational,Lung Cancer; NSCLC; NSCLC Stage IV,Standard of care immune checkpoint inhbitors,,"Jun Zhang, MD, PhD",Nilogen Oncosystems,25,2022-07-21,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05332925
NCT05419375,Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors,Phase 2,Recruiting,Interventional,Solid Tumors,Screening platform,,Hoffmann-La Roche,,15000,2022-07-22,2032-12-22,Australia; Belgium; Brazil; Canada; Chile; Colombia; Costa Rica; France; Germany; Hong Kong; India; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Poland; Serbia; Singapore; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05419375
NCT05500092,"An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Resectable Stage IIA to IIIB Non-small Cell Lung Cancer,Nivolumab; (8gy x 3); Platinum Doublet,,Montefiore Medical Center,Bristol-Myers Squibb,52,2023-01-25,2025-07-05,United States,No,https://clinicaltrials.gov/study/NCT05500092
NCT05514717,"A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",Phase 1,Recruiting,Interventional,HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2-positive Non-Small Cell Lung Cancer; HER2-positive Colorectal Cancer; HER2-positive Tumors; HER2 Low Breast Cancer,XMT-2056,,Mersana Therapeutics,,162,2023-01-24,2027-04-05,United States,No,https://clinicaltrials.gov/study/NCT05514717
NCT05520099,Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02),,Recruiting,Observational,Immunotherapy; Cancer; Bladder Cancer; Urothelial Carcinoma Bladder; Kidney Cancer; Clear Cell Renal Cell Cancer (ccRCC); Colorectal Cancer; MSI-H Colorectal Cancer; DMMR Colorectal Cancer; Head and Neck Cancer (H&N); Squamous Cell Carcinoma Head and Neck Cancer (HNSCC); Liver Cancer; Hepatocellular Carcinoma (HCC); Lung Cancer (NSCLC); NSCLC (Non-small Cell Lung Cancer); Skin Cancer; Cutaneous Melanoma; Endometrial Cancer; Solid Tumor Cancer,"Core Needle Biopsy, Forceps Biopsy, Punch Biopsy",,Elephas,,416,2023-06-26,2027-01-05,United States,No,https://clinicaltrials.gov/study/NCT05520099
NCT05566223,A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System,Phase 1/Phase 2,Not yet recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung; Metastatic Non Small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Large Cell Lung Cancer",Fludarabine; Cyclophosphamide; CISH Inactivated TIL; Aldesleukin; Pembrolizumab,,"Intima Bioscience, Inc.",,70,2023-02-05,2027-11-05,United States,No,https://clinicaltrials.gov/study/NCT05566223
NCT05584670,"A Phase 1/2, Open Label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR445877 Administered as Monotherapy or in Combination With Other Anticancer Therapies in Adults With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Solid Tumor,SAR445877; Cetuximab; ADG126; Bevacizumab; Nivolumab; Ipilimumab,,Sanofi,,542,2022-11-29,2028-06-28,Chile; Israel; Netherlands; Spain; United States,No,https://clinicaltrials.gov/study/NCT05584670
NCT05642572,"A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)",Phase 2,Recruiting,Interventional,Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8,Biospecimen Collection; Capmatinib; Computed Tomography; Magnetic Resonance Imaging; Osimertinib; Ramucirumab,,SWOG Cancer Research Network,National Cancer Institute (NCI),66,2023-05-05,2027-05-31,United States,No,https://clinicaltrials.gov/study/NCT05642572
NCT05669846,Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC,Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Healthy Donor Fecal Microbiota Transplant (hdFMT); Pembrolizumab,,Diwakar Davar,Gateway for Cancer Research,26,2025-01-08,2029-12-31,United States,No,https://clinicaltrials.gov/study/NCT05669846
NCT05715229,A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC,Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed,,Hackensack Meridian Health,MedSIR,108,2023-09-29,2026-04-28,United States,No,https://clinicaltrials.gov/study/NCT05715229
NCT05720117,"A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Solid Tumor; Advanced Solid Tumor,PYX-201,,"Pyxis Oncology, Inc",,330,2023-03-14,2027-05-05,Belgium; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05720117
NCT05785741,"A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1310 in Subjects With Advanced/Metastatic Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,DB-1310; Trastuzumab; Osimertinib,,DualityBio Inc.,,1000,2023-04-10,2026-08-31,China; United States,No,https://clinicaltrials.gov/study/NCT05785741
NCT05815173,Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC),Phase 1,Recruiting,Interventional,Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation,Sotorasib; Ladarixin,,NYU Langone Health,,40,2023-08-01,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT05815173
NCT05827614,"An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications",Phase 1,Recruiting,Interventional,Triple Negative Breast Cancer (TNBC); High Grade Serous Ovarian Carcinoma; High Grade Endometrial Carcinoma; Anogenital Cancer; Head and Neck (HNSCC); Cutaneous Squamous Cell Carcinoma (CSCC); Cervical Squamous Cell Carcinoma; ER+ Breast Cancer; Leiomyosarcoma (LMS); Undifferentiated Pleomorphic Sarcoma (UPS); Pancreatic Cancer Metastatic; Small Cell Lung Cancer,BBI-355; Erlotinib; Futibatinib; BBI-825,,Boundless Bio,,127,2023-03-24,2027-03-31,United States,No,https://clinicaltrials.gov/study/NCT05827614
NCT05845671,"A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors",Phase 1/Phase 2,Recruiting,Interventional,Lung Cancer; Non Small Cell Lung Cancer,Amivantamab 1050mg; Amivantamab 1400mg; Amivantamab (to be determined); Amivantamab (to be determined),,"University of Colorado, Denver","Janssen Research & Development, LLC",12,2023-07-17,2028-01-05,United States,No,https://clinicaltrials.gov/study/NCT05845671
NCT05853887,iNUDGE: INtegration of liqUiD Biopsy Based Next Generation Gene sEquencing in Newly Diagnosed NSCLC - A Stepped Wedge Cluster Randomized Clinical Trial,Not Applicable,Recruiting,Interventional,Non Small Cell Lung Cancer Metastatic; Newly Diagnosed NSCLC; Non-Squamous Non-Small Cell Neoplasm of Lung,iNUDGE,,Charu Aggarwal,Eli Lilly and Company,360,2023-06-15,2026-01-31,United States,No,https://clinicaltrials.gov/study/NCT05853887
NCT05887492,"A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,"Non Small Cell Lung Cancer; Solid Tumors, Adult; Lung Cancer; Lung Adenocarcinoma",TNG260; Pembrolizumab,,"Tango Therapeutics, Inc.",,126,2023-06-12,2026-06-05,United States,No,https://clinicaltrials.gov/study/NCT05887492
NCT05892068,Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance,Phase 2,Recruiting,Interventional,Metastatic Breast Cancer,Tucatinib,,Memorial Sloan Kettering Cancer Center,Pfizer; Seagen Inc.,28,2023-05-09,2028-05-09,United States,No,https://clinicaltrials.gov/study/NCT05892068
NCT06033196,Targeting Inflammation and Alloimmunity in Lung Transplant Recipients With Tocilizumab (CTOT-45),Phase 2,Recruiting,Interventional,Lung Transplant,Tocilizumab; Placebo for Tocilizumab,,National Institute of Allergy and Infectious Diseases (NIAID),,350,2024-02-13,2029-01-08,United States,No,https://clinicaltrials.gov/study/NCT06033196
NCT06050707,MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach,Phase 2,Recruiting,Interventional,Anal Squamous Cell Carcinoma,Radiotherapy - Low risk group; Radiotherapy - Standard risk group; Radiotherapy - Intermediate risk group; Radiotherapy - High risk group,,"University Health Network, Toronto",Medical College of Wisconsin,80,2023-09-29,2028-09-01,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT06050707
NCT06090266,A Phase 1/2 Study of OR502 Alone and in Combination With Other Anti-cancer Agents in Subjects With Advanced Malignancies,Phase 1/Phase 2,Recruiting,Interventional,"Cancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanoma; Non-small Cell Lung Cancer",OR502; Cemiplimab,,"OncoResponse, Inc.",,168,2023-10-24,2027-02-01,United States,No,https://clinicaltrials.gov/study/NCT06090266
NCT06116682,A Phase II Study of Amivantamab SC (Subcutaneous) in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY),Phase 2,Recruiting,Interventional,Lung Non-Small Cell Carcinoma,Amivantamab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging,,SWOG Cancer Research Network,National Cancer Institute (NCI),88,2024-11-19,2028-05-31,United States,No,https://clinicaltrials.gov/study/NCT06116682
NCT06124118,A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC,Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer,carboplatin chemotherapy; NovoTTF-200T (TTFields) System; Durvalumab,,University of Utah,,30,2024-04-04,2026-11-15,United States,No,https://clinicaltrials.gov/study/NCT06124118
NCT06151574,"Beamion LUNG 2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered Zongertinib (BI 1810631) Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Harbouring HER2 Tyrosine Kinase Domain Mutations",Phase 3,Recruiting,Interventional,"Lung Cancer, Non-squamous, Non-small Cell",zongertinib; pembrolizumab; cisplatin; carboplatin; pemetrexed,,Boehringer Ingelheim,,416,2024-02-09,2028-01-28,Argentina; Australia; Austria; Belgium; Brazil; Chile; China; France; Germany; Hong Kong; Israel; Italy; Japan; Mexico; Netherlands; Norway; Poland; Portugal; Puerto Rico; Singapore; South Korea; Spain; Sweden; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06151574
NCT06225804,"A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",Phase 1,Recruiting,Interventional,Non-Small Cell Lung Cancer,ABSK112,,"Abbisko Therapeutics Co, Ltd",,164,2024-02-22,2028-03-05,China; United States,No,https://clinicaltrials.gov/study/NCT06225804
NCT06236438,"A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",Phase 2/Phase 3,Recruiting,Interventional,Non-Small Cell Lung Cancer,Livmoniplimab; Budigalimab; Pembrolizumab; Pemetrexed; Cisplatin; Carboplatin; Carboplatin,,AbbVie,,840,2024-04-10,2031-10-05,Australia; Belgium; Chile; France; Israel; Japan; Netherlands; Puerto Rico; Spain; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06236438
NCT06252129,Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens,Not Applicable,Recruiting,Interventional,Lung Cancer; Lymph Node Metastasis; Pathologic Processes,Subjects undergoing a lung specimen lymph node dissection; Control group,,Brigham and Women's Hospital,,160,2024-07-26,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT06252129
NCT06253871,A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations,Phase 1,Recruiting,Interventional,HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer; HER2 + Breast Cancer; Brain Metastases From Solid Tumors; Brain Metastases From HER2 and Breast Cancer; CNS Metastases; HER2-Positive Solid Tumors; NSCLC (Non-small Cell Lung Cancer); HER2-positive Bladder Cancer; HER2-positive Colorectal Cancer; HER2 + Gastric Cancer; HER2-positive Gastroesophageal Cancer,IAM1363,,"Iambic Therapeutics, Inc",,243,2024-03-25,2028-03-05,France; Ireland; Netherlands; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06253871
NCT06265285,"Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",Phase 2,Recruiting,Interventional,Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignant Solid Neoplasm; Metastatic Colorectal Carcinoma; Metastatic Cutaneous Melanoma; Metastatic Esophageal Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Metastatic Urothelial Carcinoma; Recurrent Esophageal Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma; Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8; Stage IV Renal Cell Cancer AJCC v8; Unresectable Cutaneous Melanoma; Unresectable Esophageal Squamous Cell Carcinoma; Urothelial Carcinoma; Unresectable Urothelial Carcinoma,Home Health Encounter; Nivolumab; Patient Monitoring; Questionnaire Administration,,Mayo Clinic,,50,2024-04-30,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT06265285
NCT06305754,"A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan; Pemetrexed; Carboplatin; H1 Receptor Antagonist; H2 Receptor Antagonist; Acetaminophen (or equivalent); Dexamethasone (or equivalent); Steroid Mouthwash (dexamethasone or equivalent),,Merck Sharp & Dohme LLC,,520,2024-06-11,2030-06-14,Argentina; Canada; China; Colombia; France; India; Italy; Japan; Malaysia; Mexico; Poland; South Korea; Spain; Sweden; Taiwan; Thailand; Turkey (Türkiye); United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06305754
NCT06311721,"A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer",Phase 3,Recruiting,Interventional,Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer,ABP 234; Pembrolizumab (US); Pembrolizumab (EU),,Amgen,,927,2024-09-09,2028-05-29,Argentina; Austria; Brazil; Bulgaria; Chile; France; Georgia; Germany; Italy; Japan; Malaysia; Peru; Philippines; Poland; Serbia; South Africa; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06311721
NCT06312137,A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery,Phase 3,Recruiting,Interventional,Non Small Cell Lung Cancer,Sacituzumab tirumotecan; Pembrolizumab; Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Paclitaxel; Rescue medication,,Merck Sharp & Dohme LLC,,780,2024-04-03,2034-10-23,Argentina; Australia; Austria; Belgium; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Peru; Poland; Portugal; Romania; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06312137
NCT06385262,"Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301",Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer,Alirocumab; Cemiplimab; Chemotherapy,,Duke University,Regeneron Pharmaceuticals,126,2025-03-17,2029-10-30,United States,No,https://clinicaltrials.gov/study/NCT06385262
NCT06400472,"A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",Phase 1,Recruiting,Interventional,"Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Triple Negative Breast Neoplasms; Pancreatic Neoplasm; Colorectal Neoplasms",LY4170156; bevacizumab; carboplatin; Itraconazole; pembrolizumab,,Eli Lilly and Company,,495,2024-05-20,2027-04-05,Australia; France; Italy; Japan; South Korea; Spain; United States,No,https://clinicaltrials.gov/study/NCT06400472
NCT06403436,"A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor; Adult Solid Tumor; Adult Disease; Cancer; NSCLC; EGFR; KRAS G12C; Squamous Cell Lung Cancer,TT125-802,,TOLREMO therapeutics AG,,50,2023-11-07,2026-12-05,Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT06403436
NCT06422143,Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer,Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer; NSCLC,Pembrolizumab; sac-TMT; Carboplatin; Paclitaxel; Nab-paclitaxel,,Merck Sharp & Dohme LLC,,851,2024-06-10,2031-02-12,Argentina; Austria; Brazil; Canada; Chile; China; Colombia; Czechia; France; Germany; Hungary; Ireland; Israel; Italy; Japan; Peru; Poland; Romania; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Arab Emirates; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06422143
NCT06427941,"A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Metastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma; Alpha-fetoprotein (AFP)-Producing Gastric Cancer; Extragonadal Yolk Sac Tumors; Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer,BGB-B2033; Tislelizumab; Bevacizumab,,BeOne Medicines,,140,2024-07-23,2026-12-31,China; New Zealand; South Korea; United States,No,https://clinicaltrials.gov/study/NCT06427941
NCT06463665,A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance,Phase 2,Recruiting,Interventional,Advanced Non-squamous Non-small-cell Lung Cancer; Advanced Squamous Non-Small Cell Lung Carcinoma; Metastatic Non-squamous Non Small Cell Lung Cancer; Metastatic Squamous Non-Small Cell Lung Carcinoma; Non-small Cell Lung Cancer; Non-small Cell Lung Cancer Stage III; Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent,"Olvimulogene nanivacirepvec; Platinum chemotherapy: carboplatin or cisplatin; Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC; Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab; Docetaxel",,Genelux Corporation,"Newsoara Biopharma Co., Ltd.",142,2024-09-26,2029-07-05,United States,No,https://clinicaltrials.gov/study/NCT06463665
NCT06465069,"A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors",Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; Recurrent Solid Tumor; Advanced Solid Tumor; Urinary Bladder Neoplasm; Triple Negative Breast Cancer; Non-small Cell Lung Cancer; Esophageal Cancer; Pancreatic Cancer; Ovarian Cancer; Cervical Cancer; Head and Neck Squamous Cell Carcinoma; Prostate Cancer; Renal Pelvis Cancer; Bladder Cancer,LY4052031,,Eli Lilly and Company,,420,2024-07-01,2027-05-05,Australia; France; Japan; South Korea; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06465069
NCT06472245,"A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor",Phase 3,Recruiting,Interventional,Patients With Non-Small Cell Lung Cancer,OSE2101; Docetaxel; NGS HLAA2 assay,,OSE Immunotherapeutics,Exystat; Genome Diagnostics (GenDx),363,2024-12-03,2028-12-15,Belgium; Canada; France; Germany; Greece; Hungary; Italy; Netherlands; Poland; Portugal; Romania; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06472245
NCT06545331,A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors,Phase 1,Recruiting,Interventional,Locally Advanced or Metastatic Solid Tumors; Esophageal Squamous Cell Cancer; Head and Neck Squamous Cell Cancer; NSCLC (Non-small Cell Lung Cancer); Hormone-receptor-positive Breast Cancer; Triple Negative Breast Cancer (TNBC),XB010; Pembrolizumab,,Exelixis,,396,2024-08-06,2027-10-20,United States,No,https://clinicaltrials.gov/study/NCT06545331
NCT06548672,"A Phase Ia/Ib, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Cancer; Metastatic Solid Tumor,BC3195,,"Biocity Biopharmaceutics Co., Ltd.",,148,2024-06-24,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT06548672
NCT06561386,"A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer,Nivolumab; Relatlimab; Pembrolizumab; Carboplatin; Pemetrexed; Cisplatin,,Bristol-Myers Squibb,,1000,2024-10-07,2032-08-04,Argentina; Australia; Austria; Belgium; Brazil; Chile; China; Colombia; Denmark; France; Germany; India; Ireland; Italy; Japan; Mexico; Netherlands; New Zealand; Poland; Portugal; Romania; Saudi Arabia; South Africa; South Korea; Spain; Switzerland; Taiwan; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06561386
NCT06566443,Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer,Phase 1,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Honokiol,,The Methodist Hospital Research Institute,,15,2024-11-08,2027-08-05,United States,No,https://clinicaltrials.gov/study/NCT06566443
NCT06568939,"A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer",Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer,Telisotuzumab Vedotin,,AbbVie,,150,2025-01-20,2028-02-05,China; Israel; Japan; Serbia; Singapore; United States,No,https://clinicaltrials.gov/study/NCT06568939
NCT06593522,"A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,MTAP-deleted NSCLC,AMG 193,,Amgen,,200,2024-12-26,2030-11-29,Australia; Brazil; Canada; China; Czechia; Hong Kong; Japan; Latvia; Netherlands; Portugal; Singapore; South Korea; Switzerland; Taiwan; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06593522
NCT06627647,"A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)",Phase 3,Recruiting,Interventional,Non-squamous Non-small Cell Lung Cancer,Rilvegostomig; Pembrolizumab; Carboplatin; Cisplatin; Pemetrexed,,AstraZeneca,,878,2024-11-27,2030-03-25,Argentina; Australia; Belgium; Brazil; Canada; China; France; Germany; Hungary; India; Italy; Japan; Malaysia; Netherlands; Peru; Poland; Puerto Rico; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06627647
NCT06657222,"A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors; HNSCC; SCLC; NSCLC; TNBC - Triple-Negative Breast Cancer; CRC,TUB-030,,Tubulis GmbH,,130,2024-12-13,2028-12-05,Canada; United States,No,https://clinicaltrials.gov/study/NCT06657222
NCT06671613,Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer,Not Applicable,Recruiting,Interventional,Stage IV NSCLC; NSCLC; Immunotherapy; Fasting Mimicking Diet,FMD; Regular Diet Plus FMD,,VA Office of Research and Development,Indiana University; US Department of Veterans Affairs Cooperative Studies Program; L-Nutra Inc,66,2025-10-27,2030-12-31,United States,No,https://clinicaltrials.gov/study/NCT06671613
NCT06695845,"A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",Phase 2,Recruiting,Interventional,Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Ovarian Cancer; Urothelial Carcinoma; Salivary Gland Cancer; Pancreatic Cancer; HER-2 Protein Overexpression,Zanidatamab,,Jazz Pharmaceuticals,Jazz Pharmaceuticals Ireland Limited,200,2025-01-14,2027-12-31,South Korea; United States,No,https://clinicaltrials.gov/study/NCT06695845
NCT06712745,Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung,Early Phase 1,Recruiting,Interventional,"Cancer, Lung; Metastasis",Personalized Ultra-fractionated stereotactic ablative radiotherapy (PULSAR),,University of Texas Southwestern Medical Center,Elekta Limited,30,2025-09-19,2028-12-05,United States,No,https://clinicaltrials.gov/study/NCT06712745
NCT06780085,"KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Raludotatug Deruxtecan; Ifinatamab Deruxtecan; Docetetaxel,,Merck Sharp & Dohme LLC,Daiichi Sankyo,96,2025-05-13,2032-03-12,Chile; Germany; Greece; Hungary; Israel; Italy; Poland; Spain; United States,No,https://clinicaltrials.gov/study/NCT06780085
NCT06780098,"KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)",Phase 2,Recruiting,Interventional,Lung Neoplasm,R-DXD; I-DXD; Docetaxel,,Merck Sharp & Dohme LLC,Daiichi Sankyo,144,2025-05-28,2032-03-02,Chile; China; Germany; Greece; Hungary; Israel; Italy; Poland; Spain; United States,No,https://clinicaltrials.gov/study/NCT06780098
NCT06814496,RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3,Phase 1/Phase 2,Recruiting,Interventional,Melanoma; Medullary Thyroid Cancer; Sinonasal Undifferentiated Carcinoma; Esthesioneuroblastoma; Bladder Cancer; Testicular Cancer; Glioblastoma Multiforme; Cervical Cancer; Large Cell Neuroendocrine Carcinoma of the Lung; Non Small Cell Lung Cancer; Merkel Cell Carcinoma,Tarlatamab; Concurrent Radiation Therapy; Sequential Radiation therapy,,University of Arizona,Amgen,30,2025-09-08,2030-05-05,United States,No,https://clinicaltrials.gov/study/NCT06814496
NCT06875310,"A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",Phase 3,Recruiting,Interventional,"Carcinoma, Non-Small-Cell Lung",Adagrasib; Pembrolizumab; Carboplatin; Pemetrexed; Placebo; Cisplatin,,Mirati Therapeutics Inc.,,630,2025-04-24,2032-04-30,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Chile; China; Colombia; Croatia; France; Germany; Greece; Hong Kong; Hungary; India; Ireland; Israel; Italy; Japan; Mexico; Netherlands; Poland; Portugal; Romania; Saudi Arabia; South Korea; Spain; Switzerland; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06875310
NCT06933329,Phase 2 Study of Zelenectide Pevedotin in Participants With Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer,Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer,Zelenectide pevedotin (BT8009),,BicycleTx Limited,,73,2025-07-18,2029-02-28,France; Spain; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06933329
NCT06973564,"A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumors,JAB-23E73; JAB-23E73; JAB-23E73,,"Jacobio Pharmaceuticals Co., Ltd.",,294,2025-05-29,2028-02-05,United States,No,https://clinicaltrials.gov/study/NCT06973564
NCT06975293,"Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer; Metastatic Melanoma; Metastatic Endometrial Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Solid Tumor,STC-15 in combination with toripalimab,,STORM Therapeutics LTD,"Coherus Oncology, Inc.",188,2025-05-05,2026-01-29,United States,No,https://clinicaltrials.gov/study/NCT06975293
NCT06996782,"A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced or Metastatic Non-small Cell Lung Cancer,Rilvegostomig; AB248; Cisplatin; Carboplatin; Pemetrexed; Paclitaxel; Nab-paclitaxel; Ramucirumab,,AstraZeneca,,152,2025-11-24,2029-02-23,Belgium; Brazil; China; France; Georgia; Germany; Italy; Japan; Malaysia; Moldova; Netherlands; Peru; Poland; Serbia; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United States,No,https://clinicaltrials.gov/study/NCT06996782
NCT07005102,"A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer",Phase 2/Phase 3,Recruiting,Interventional,Non-Squamous Non-Small Cell Lung Cancer,Standard of Care; Telisotuzumab Adizutecan; Osimertinib (Osi),,AbbVie,,694,2025-08-03,2031-12-05,Australia; Belgium; Israel; Italy; Japan; Portugal; Singapore; South Korea; Spain; Taiwan; United States,No,https://clinicaltrials.gov/study/NCT07005102
NCT07073183,A Phase I Dose-Finding Study to Evaluate Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC),Phase 1,Not yet recruiting,Interventional,Squamous NSCLC,CV09070101 mRNA vaccine (CVHNLC) 50 µg; CV09070101 mRNA vaccine (CVHNLC) 100 µg; CV09070101 mRNA vaccine (CVHNLC) 200 µg; CV09070101 mRNA vaccine (CVHNLC) 400 µg; CV09070101 mRNA vaccine (CVHNLC) 400 µg,,CureVac,,36,2025-07-30,2029-12-31,France; Spain; United States,No,https://clinicaltrials.gov/study/NCT07073183
NCT07132918,The cARdiac Radiation Therapy Sparing (HEARTS) for Thoracic Cancers,Phase 2,Recruiting,Interventional,Non-Small Cell Lung Cancer (Stage III); Esophageal Cancer Stage I-III; Esophagogastric Cancer Stage I-III; Thymoma and Thymic Carcinoma Stage II-III; Other Cancers in the Thoracic Region,MRgART; LINAC,,"University of Wisconsin, Madison","National Heart, Lung, and Blood Institute (NHLBI)",60,2025-10-08,2029-03-05,United States,No,https://clinicaltrials.gov/study/NCT07132918
